Article
Author(s):
EyePoint Pharmaceuticals announces first patient dosed in global Phase 3 LUGANO clinical trial of Duravyu for wet AMD
Week in Review - October 5, 2024
Study estimates glaucoma and vision-affecting glaucoma prevalence by demographic factors
Innovation Series: AI’s impact on managing ocular surface disease with Peter J. McDonnell, MD, and Laura M. Periman, MD
The top 10 takeaways from AAO 2024
Real-world evidence on latest retinal disease therapies
